

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute, and is not intended to be, an invitation or offer to acquire, purchase or subscribe for, or offer to sell or a solicitation of any offer to buy securities in Hong Kong, the People's Republic of China or elsewhere.

PW MEDTECH GROUP LIMITED

普华和顺集团公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1358)

PROGRESS ON PROPOSED SPIN-OFF OF SICHUAN RUIJIAN MEDICAL

Reference is made to the announcements of the Company dated May 20, 2024, July 2, 2024 and October 2, 2024 in relation to the Proposed Spin-off (the “**Announcements**”). Unless otherwise defined, the terms used herein shall have the same meaning as those defined in the Announcements. As disclosed in the Announcements, the NEEQS Quotation was approved by the NEEQ Co., Ltd. The Board hereby provides the latest update on the Proposed Spin-off to its Shareholders.

The Board is pleased to announce that the NEEQS Quotation was successfully completed on December 5, 2024. As part of the Proposed Spin-off, Sichuan Ruijian Medical, subject to the then market conditions and its strategic development needs, may proceed the Subsequent Listing after the NEEQS Quotation. It is intended that Sichuan Ruijian Medical will remain as a subsidiary of the Company upon completion of the Subsequent Listing subject to the Company and its auditor’s assessment under HKFRS. The Subsequent Listing, if materialized, may constitute a deemed disposal and a notifiable transaction of the Company under Chapter 14 of the Listing Rules. The Company will comply with the relevant announcement and/or Shareholders’ approval requirements (if applicable) where appropriate. Further announcement(s) will be made by the Company in accordance with the Listing Rules as and when appropriate.

Shareholders and potential investors should note that the Subsequent Listing is subject to, among other things, the prevailing market conditions and approvals from relevant authorities, including the CSRC and the Beijing Stock Exchange. Accordingly, Shareholders and potential investors should be aware that the Company does not guarantee that the Subsequent Listing will materialize, nor the timing thereof. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
PW Medtech Group Limited
普华和顺集团公司
Yue'e Zhang
Chairman & Chief Executive Officer

Hong Kong, December 5, 2024

As at the date of this announcement, the Board comprises one executive director, namely, Ms. Yue'e Zhang; two non-executive directors, namely Mr. Jiang Liwei and Mr. Lin Junshan; and three independent non-executive directors, namely, Mr. Wang Xiaogang, Mr. Chen Geng and Ms. Wang Fengli.